Earnings Preview: What to Expect From Insulet's Report

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Valued at a market cap of $19.7 billion, the company’s Omnipod Insulin Management System is equipped with a self-adhesive, small, and lightweight disposable tubeless Omnipod device along with a wireless and handheld Personal Diabetes Manager (PDM). It is expected to announce its fiscal Q4 earnings results after the market closes on Thursday, Feb. 20. 

Prior to this event, analysts expect the medical device company to report a profit of $1.05 per share, down 25% from $1.40 per share in the year-ago quarter. The company has surpassed Wall Street's earnings estimates in three of the last four quarters while missing on another occasion. Its earnings of $0.90 per share in the previous quarter outpaced the consensus estimates by a significant margin of 16.9%.